Cytek Biosciences Inc - Asset Resilience Ratio
Cytek Biosciences Inc (CTKB) has an Asset Resilience Ratio of 43.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cytek Biosciences Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Cytek Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cytek Biosciences Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Cytek Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Cytek Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $196.56 Million | 43.77% |
| Total Liquid Assets | $196.56 Million | 43.77% |
Asset Resilience Insights
- Very High Liquidity: Cytek Biosciences Inc maintains exceptional liquid asset reserves at 43.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytek Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Cytek Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Cytek Biosciences Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Cytek Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.98% | $170.68 Million | $461.54 Million | +1.11pp |
| 2024-12-31 | 35.86% | $179.15 Million | $499.50 Million | +16.63pp |
| 2023-12-31 | 19.24% | $95.11 Million | $494.46 Million | +10.66pp |
| 2022-12-31 | 8.58% | $44.55 Million | $519.48 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $463.31 Million | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more